# Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial

> **NCT06857305** · PHASE3 · ENROLLING_BY_INVITATION · sponsor: **Ma Fei，MD** · enrollment: 192 (estimated)

## Conditions studied

- Breast Cancer Metastatic

## Interventions

- **DRUG:** Eribulin biweekly regimen
- **DRUG:** Eribulin standard regimen

## Key facts

- **NCT ID:** NCT06857305
- **Lead sponsor:** Ma Fei，MD
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2023-07-13
- **Primary completion:** 2026-07-13
- **Final completion:** 2026-07-13
- **Target enrollment:** 192 (ESTIMATED)
- **Last updated:** 2025-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06857305

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06857305, "Efficacy and Safety of Biweekly Regimen of Eribulin Versus a Standard Regimen for the Treatment of Locally Recurrent or Metastatic HER2-negative Breast Cancer: a Multicenter, Randomized, Open-label, Phase III Trial". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06857305. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*